Funding news
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Integrated research and care, AI driving the future of neurology
SAN DIEGO — Challenges continue to grow in neurology, from the increasing prevalence of Parkinson’s, Alzheimer’s and other neurodegenerative diseases to decreases in funding for the research investigating their treatment. …
Free to read? Not known for this outlet.
Read at Healio →National Plan for Alzheimer's and Dementia Gets an Update From HHS
(MedPage Today) -- HHS announced an update Thursday to the National Plan to Address Alzheimer's Disease and Related Dementias that includes investment in projects focused on earlier detection and intervention. "Under President Trump, HHS is shifting...
Free to read? Not known for this outlet.
Read at MedPage Today → Archived copy (23 Oct 2026), Internet Archive$100 Million Increase for Alzheimer's and Dementia Research Signed Into Law
The FY2026 federal spending package signed into law includes a $100 million increase for Alzheimer's and dementia research at NIH, bringing total funding to about $3.9 billion, plus $41.5 million for the CDC's BOLD Infrastructure for Alzheimer's Act, the highest level since that law's enactment.
Why it matters: Converts the earlier Senate committee proposal into enacted law, securing real funding increases for research and public-health infrastructure despite a contentious broader budget environment.
Read at Alzheimer's Association → Archived copy (25 Aug 2026), Internet ArchiveHouse and Senate Appropriators Endorse NIH Budget Increase, Reject Trump's Proposed Cuts
Congressional appropriators set the NIH's overall budget at $48.7 billion for FY2026, a $415 million increase over FY2025, rejecting the White House's proposed cuts, while allowing a new multiyear-grant funding strategy to continue that had already resulted in thousands fewer awards to scientists in 2025.
Why it matters: Shows Congress broadly rebuffing proposed NIH cuts that had alarmed the Alzheimer's research community, though changes to multiyear grant funding could still constrain some researchers.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (20 Jan 2026), Internet ArchiveNIH releases Alzheimer’s Disease and Related Dementias Research Progress Report and FY27 Professional Judgment Budget
NIH released the FY 2027 Professional Judgment Budget for Alzheimer’s Disease and Related Dementias and the NIH Scientific Progress Report.
Why it matters: The NIH has released its FY 2027 Professional Judgment Budget and Scientific Progress Report for Alzheimer's Disease and Related Dementias.
Read at NIH National Institute on Aging → Archived copy (2 Aug 2026), Internet ArchivePotential Stroke and Dementia Therapies Put on Hold at UCLA
Federal funding suspensions tied to a Trump administration policy targeting universities cut off support for roughly 58 UCLA studies related to Alzheimer's, dementia, and other neurodegenerative diseases, including about $23 million backing the Neurology Department's work.
Why it matters: Shows how federal-university funding disputes can directly stall dementia drug and therapy research, including a UCLA-developed compound that had reached a pivotal testing stage.
Free to read? Not known for this outlet.
Read at UCLA newsroom → Archived copy (23 Jan 2026), Internet ArchiveSenate Appropriations Committee Approves $100 Million Increase for Alzheimer's Research
The Senate Appropriations Committee approved a $100 million increase in NIH funding for Alzheimer's and dementia research for FY2026, which would bring total annual federal funding to about $3.9 billion, plus $41.5 million for CDC's Healthy Brain Initiative/BOLD Act programs.
Why it matters: Signals continued bipartisan congressional support for dementia research funding even amid broader proposed NIH budget cuts in the administration's FY2026 request.
Read at Alzheimer's Association → Archived copy (21 May 2026), Internet ArchiveLifesaving Alzheimer's Research Delayed by Trump Funding Cuts
A nearly $36 million NIH grant to a UC Davis dementia study was terminated in March 2025 before being reinstated after appeal, while 14 of 35 NIH-funded Alzheimer's Disease Research Centers faced funding uncertainty, including a $3 million loss at Columbia.
Why it matters: Interruptions to federal funding threaten ongoing patient studies, brain-bank operations, and the multi-institution collaborations needed to advance treatments.
May need a subscription Based on the outlet (Scientific American), not a check of this article.
Read at Scientific American → Archived copy (15 Aug 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.